Characterization of Corticospinal Excitability During Progressive Skin Cooling

December 2, 2022 updated by: Dr.Gordon Giesbrecht, University of Manitoba
This study characterizes the changes in corticospinal excitability that accompany basic cold stress via skin cooling that result in reduced skin or core temperature and shivering.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Cold stress is known to impair both fine and gross motor movement. Reductions in performance may have life threatening consequences in survival situations where maintenance of muscle control is necessary. Much of the effects cooling has on muscle performance is directly due to its effects on muscle tissue itself, whereas less is known about the effects on the central nervous system. Therefore, the purpose of the study was to characterize corticospinal excitability that accompanies basic cold stress via progressive skin cooling, resulting in reductions in skin (Tsk) or core (Tco) temperature and shivering.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Manitoba
      • Winnipeg, Manitoba, Canada, R3T 2N2
        • 211 Max Bell Centre, University of Manitoba

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy adult
  • Right Handed
  • Pass Magnetic Stimulation Safety Checklist
  • Pass Medical Screening Questionnaire

Exclusion Criteria:

  • Left Handed
  • Any adverse responses to cold exposure (Raynaud's Syndrome)
  • Cardiorespiratory Disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control Condition
Subjects will sit at rest wearing a liquid perfused suit containing thermoneutral water for 60 min. The suit will not be turned on during this period.
Experimental: Cold Condition
Subjects will be cooled for 60-90 min at ~ 4-10°C using a liquid perfused suit. Subjects will then be rewarmed for 30 min at ~ 41°C using the liquid perfused suit.
60-90 mins of cooling via a liquid perfused suit circulating ~4-10°C liquid.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Corticospinal Excitability
Time Frame: at 0, 20, 40, 60 and 90 minutes
Motor Evoked Potentials (MEP) as a percentage of the maximal compound muscle action potential (Mmax) measured via MEG at the Biceps Brachii will serve as the indices of Corticospinal excitbaility
at 0, 20, 40, 60 and 90 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Spinal Excitability
Time Frame: at 0, 20, 40, 60 and 90 minutes
Cervicomedullary Motor Evoked Potentials (CMEP) as a percentage of the maximal compound muscle action potential (Mmax) measured via MEG at the Biceps Brachii will serve as the indices of spinal excitability
at 0, 20, 40, 60 and 90 minutes
Change in Skin Temperature
Time Frame: at 0, 20, 40, 60 and 90 minutes
Mean skin temperature of 7 sites
at 0, 20, 40, 60 and 90 minutes
Change in Core Temperature
Time Frame: at 0, 20, 40, 60 and 90 minutes
Esophageal temperature is the most accurate method representing the temperature of the heart.
at 0, 20, 40, 60 and 90 minutes
Change in Metabolic Heat Production
Time Frame: at 0, 20, 40, 60 and 90 minutes
Metabolic heat production serves as an objective way to quantify shivering thermogenesis.
at 0, 20, 40, 60 and 90 minutes

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Peripheral nerve excitability
Time Frame: at 0, 20, 40, 60 and 90 minutes
Excitability of the peripheral nerve measured via EMG at the biceps brachia ( the maximal compound motor action potential (Mmax).
at 0, 20, 40, 60 and 90 minutes
Change in Maximal Voluntary Contraction of Elbow Flexors
Time Frame: at 0, 20, 40, 60 and 90 minutes
Maximal Isometric Force of elbow flexors measured in kg of force
at 0, 20, 40, 60 and 90 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gordon Giesbrecht, PhD, University of Manitoba

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 22, 2019

Primary Completion (Actual)

March 1, 2022

Study Completion (Actual)

June 1, 2022

Study Registration Dates

First Submitted

November 26, 2019

First Submitted That Met QC Criteria

January 31, 2020

First Posted (Actual)

February 5, 2020

Study Record Updates

Last Update Posted (Estimate)

December 6, 2022

Last Update Submitted That Met QC Criteria

December 2, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E2018:047 (HS21827)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypothermia Due to Cold Environment

Clinical Trials on Cold Stress

3
Subscribe